Today's financial landscape saw diverse developments, with the commodities sector active as Red Rock Resources benefited from surging gold prices and Caspian Sunrise diversified into new minerals including titanium, zirconium, and rare earths. AstraZeneca achieved a significant oncology milestone with Enhertu receiving its tenth Breakthrough Therapy Designation for early breast cancer. Corporate actions included Zegona Communications approving a substantial €1.4 billion special dividend alongside a share reduction, while Coro Energy secured funding for strategic growth through a new placing, and multiple companies, including Amigo Holdings and Grainger, reported significant insider share purchases signaling management confidence.
Red Rock Resources RRR announced its final audited results for the year ended 30 June 2025, highlighting its focus on gold and copper assets across Australia, Kenya, Côte d'Ivoire, and Burkina Faso. The period saw a significant 40.4% increase in the gold price, reaching USD 3,264.03 per troy ounce, positively impacting the company's asset valuations. This strong commodity environment is expected to continue benefiting the company's exploration and production interests into 2026. The report also details progress on estimated gold mineral resources in Kenya.
Caspian Sunrise CASP announced a significant strategic shift with the acquisition of Tau-Cen LLP, a Kazakh-registered limited liability partnership. This marks the company's first investment outside of oil and gas, adding titanium, zirconium, and gold to its mineral portfolio. The acquisition also brings exposure to rare earth elements bound within the zirconium concentrate, signaling a deliberate diversification strategy for the group. The number of shares in issue following the issue of the acquisition shares was amended to 2,361,529,923.
AstraZeneca AZN and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation by the US Food and Drug Administration. The designation is for adult patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant treatment and are at high risk of recurrence. This BTD, the tenth for Enhertu, is based on results from the DESTINY-Breast05 Phase III trial and aims to expedite the drug's development and regulatory review process, addressing a significant unmet medical need.
Unicorn AIM VCT UAV confirmed the completion of its partial disposal of Hasgrove Limited, which generated net cash proceeds of £66.2 million. The investment trust has reinvested £22 million into a Newco to maintain a stake in the Hasgrove business, reflecting a balanced approach to capital management. The updated valuation from this transaction was already incorporated into the November 2025 Net Asset Value. The Board is scheduled to meet in January 2026 to discuss and potentially declare a special dividend for shareholders.
Zegona Communications ZEG announced that its shareholders overwhelmingly approved a special resolution to effect a 69% reduction in the company's ordinary shares at a recent General Meeting. This crucial approval greenlights the payment of a substantial €1.4 billion special dividend, scheduled for 7 January 2026. The dividend will be paid to shareholders on the register as of 19 December 2025, marking a significant capital return event. Votes were received in respect of 184,351,154 ordinary shares, representing approximately 78.26% of those entitled to vote.
Coro Energy CORO announced the successful completion of its placing bookbuild, contingent on shareholder approval. As a developer of renewable energy projects in Southeast Asia, this fundraising is a crucial step to secure capital for its ongoing and future initiatives. The company's ability to raise funds through this placing underscores investor confidence in its strategic direction and growth potential within the burgeoning renewable energy sector. Further details are expected following the shareholder meeting.
Amigo Holdings AMGO reported significant insider share purchases, with CEO Nicholas Beal acquiring 4,278,427 ordinary shares and Non-Executive Director Jonathan Roe buying 1,910,425 shares. These transactions, priced at 0.3 pence per share, occurred through a Winterflood Retail Access Platform offer for existing shareholders and open market purchases. The substantial volume of these purchases signals robust management confidence in the company's valuation and recovery trajectory, following recent corporate developments.
Hammerson reported a notable share acquisition by Clare Wilkinson, a person closely associated with Executive Director Rob Wilkinson. The purchase involved 155,718 ordinary shares at an average price of £3.226856 per share, totaling approximately £500,000. This substantial transaction suggests strong insider conviction regarding the property company's current valuation and future outlook amidst ongoing market dynamics. The notification was made in accordance with the requirements of the UK Market Abuse Regulation.
Phoenix Copper PXC announced that Andre Cohen, an Advisory Board member, acquired 300,000 ordinary shares at 1.95 pence per share. This purchase, which took place on 18 December 2025, increases his beneficial interest to 0.36% of the company's issued share capital. Although from an advisory role, the substantial volume of shares bought signals insider confidence in the AIM-quoted base and precious metals producer and its exploration projects, particularly relevant for a company of its size.